Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US court vacates Suboxone injunction

Executive Summary

Dr Reddy’s Laboratories plans to resume its launch activities of the first generic of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film formulation “as soon as permitted” after a US Court of Appeals vacated and remanded a district court’s preliminary injunction in a majority 2-1 decision. Appeals court judge Pauline Newman offered a dissenting opinion. As Generics bulletin went to press, Dr Reddy’s had not announced a launch.


Related Content

Alvogen and Dr Reddy’s US Suboxone Rivals Face Off Against Sandoz’ Authorized Generic
Indivior Sets Out Next Steps As It Braces For Suboxone Rivals
US Suboxone Generics Likely To Hit On Monday: Here’s All You Need To Know



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts